{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T21:15:23Z","timestamp":1769202923807,"version":"3.49.0"},"reference-count":227,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T00:00:00Z","timestamp":1627516800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.bbadis.2021.166235","type":"journal-article","created":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T23:39:48Z","timestamp":1627688388000},"page":"166235","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Nuclear receptors in liver fibrosis"],"prefix":"10.1016","volume":"1867","author":[{"given":"Philipp","family":"K\u00f6nigshofer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ksenia","family":"Brusilovskaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oleksandr","family":"Petrenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedikt Silvester","family":"Hofer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Schwabl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Trauner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Reiberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbadis.2021.166235_bb0005","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0016-5085(63)80130-4","article-title":"Capillarization of hepatic sinusoids in man","volume":"44","author":"Schaffner","year":"1963","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbadis.2021.166235_bb0010","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41575-020-00372-7","article-title":"Molecular and cellular mechanisms of liver fibrosis and its regression","volume":"18","author":"Kisseleva","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbadis.2021.166235_bb0015","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1172\/JCI24282","article-title":"Liver fibrosis","volume":"115","author":"Bataller","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbadis.2021.166235_bb0020","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1152\/physrev.00013.2007","article-title":"Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver","volume":"88","author":"Friedman","year":"2008","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.bbadis.2021.166235_bb0025","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/gut.50.4.571","article-title":"Hepatic stellate cells: role in microcirculation and pathophysiology of portal hypertension","volume":"50","author":"Reynaert","year":"2002","journal-title":"Gut"},{"key":"10.1016\/j.bbadis.2021.166235_bb0030","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1038\/ncomms3823","article-title":"Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology","volume":"4","author":"Mederacke","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbadis.2021.166235_bb0035","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev-pathol-011110-130246","article-title":"Pathogenesis of liver fibrosis","volume":"6","author":"Hernandez-Gea","year":"2011","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.bbadis.2021.166235_bb0040","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jhep.2011.02.001","article-title":"Epithelial-mesenchymal transition in chronic liver disease: fibrogenesis or escape from death?","volume":"55","author":"Pinzani","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbadis.2021.166235_bb0045","doi-asserted-by":"crossref","first-page":"110413","DOI":"10.1016\/j.biopha.2020.110413","article-title":"Study on the relationship between hepatic fibrosis and epithelial-mesenchymal transition in intrahepatic cells","volume":"129","author":"Chen","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bbadis.2021.166235_bb0050","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.ajpath.2011.06.001","article-title":"Role of endothelial-mesenchymal transition (EndoMT) in the pathogenesis of fibrotic disorders","volume":"179","author":"Piera-Velazquez","year":"2011","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bbadis.2021.166235_bb0055","doi-asserted-by":"crossref","first-page":"G492","DOI":"10.1152\/ajpgi.00428.2016","article-title":"A small population of liver endothelial cells undergoes endothelial-to-mesenchymal transition in response to chronic liver injury","volume":"313","author":"Ribera","year":"2017","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.bbadis.2021.166235_bb0060","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1186\/1755-1536-5-S1-S26","article-title":"Reversibility of liver fibrosis","volume":"5","author":"Pellicoro","year":"2012","journal-title":"Fibrogenesis Tissue Repair"},{"key":"10.1016\/j.bbadis.2021.166235_bb0065","doi-asserted-by":"crossref","first-page":"314","DOI":"10.4269\/ajtmh.1985.34.314","article-title":"Reversal of hepatic fibrosis after praziquantel therapy of murine schistosomiasis","volume":"34","author":"Morcos","year":"1985","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.bbadis.2021.166235_bb0070","doi-asserted-by":"crossref","unstructured":"Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 2015;149:367\u201378 e5; quiz e14\u20135.","DOI":"10.1053\/j.gastro.2015.04.005"},{"key":"10.1016\/j.bbadis.2021.166235_bb0075","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.bbadis.2021.166235_bb0080","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.jhep.2011.09.024","article-title":"Clinical evidence for the regression of liver fibrosis","volume":"56","author":"Ellis","year":"2012","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbadis.2021.166235_bb0085","first-page":"9","article-title":"Liver fibrosis: mechanistic concepts and therapeutic perspectives","author":"Roehlen","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.bbadis.2021.166235_bb0090","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/0-387-24180-9_5","article-title":"NF-kappaB, an evolutionarily conserved mediator of immune and inflammatory responses","volume":"560","author":"Xiao","year":"2005","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.bbadis.2021.166235_bb0095","doi-asserted-by":"crossref","first-page":"6853","DOI":"10.1038\/sj.onc.1203239","article-title":"Activators and target genes of Rel\/NF-kappaB transcription factors","volume":"18","author":"Pahl","year":"1999","journal-title":"Oncogene"},{"key":"10.1016\/j.bbadis.2021.166235_bb0100","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/nm1663","article-title":"TLR4 enhances TGF-beta signaling and hepatic fibrosis","volume":"13","author":"Seki","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbadis.2021.166235_bb0105","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nrgastro.2010.213","article-title":"NF-kappaB in the liver--linking injury, fibrosis and hepatocellular carcinoma","volume":"8","author":"Luedde","year":"2011","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbadis.2021.166235_bb0110","doi-asserted-by":"crossref","first-page":"24359","DOI":"10.1074\/jbc.M211051200","article-title":"Basal expression of IkappaBalpha is controlled by the mammalian transcriptional repressor RBP-J (CBF1) and its activator Notch1","volume":"278","author":"Oakley","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbadis.2021.166235_bb0115","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/sj.cdd.4401979","article-title":"Regulation of myofibroblast transdifferentiation by DNA methylation and MeCP2: implications for wound healing and fibrogenesis","volume":"14","author":"Mann","year":"2007","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.bbadis.2021.166235_bb0120","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/hep.21802","article-title":"Nuclear factor-kappaB and the hepatic inflammation-fibrosis-cancer axis","volume":"46","author":"Elsharkawy","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.bbadis.2021.166235_bb0125","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1476-5381.2008.00030.x","article-title":"Nuclear receptors as therapeutic targets in cholestatic liver diseases","volume":"156","author":"Zollner","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bbadis.2021.166235_bb0130","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/hep.22668","article-title":"Nuclear bile acid receptor farnesoid X receptor meets nuclear factor-kappaB: new insights into hepatic inflammation","volume":"48","author":"Wagner","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.bbadis.2021.166235_bb0135","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1002\/hep.22519","article-title":"Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response","volume":"48","author":"Wang","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.bbadis.2021.166235_bb0140","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2005.06.029","article-title":"Molecular determinants of crosstalk between nuclear receptors and toll-like receptors","volume":"122","author":"Ogawa","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.bbadis.2021.166235_bb0145","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0092-8674(00)80726-6","article-title":"A unified nomenclature system for the nuclear receptor superfamily","volume":"97","author":"Nuclear Receptors Nomenclature","year":"1999","journal-title":"Cell"},{"key":"10.1016\/j.bbadis.2021.166235_bb0150","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1677\/jme.0.0190207","article-title":"Evolution of the nuclear receptor superfamily: early diversification from an ancestral orphan receptor","volume":"19","author":"Laudet","year":"1997","journal-title":"J. Mol. Endocrinol."},{"key":"10.1016\/j.bbadis.2021.166235_bb0155","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.addr.2010.08.007","article-title":"Structural and functional insights into nuclear receptor signaling","volume":"62","author":"Jin","year":"2010","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bbadis.2021.166235_bb0160","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/clpt.2010.2","article-title":"Nuclear receptors, inflammation, and liver disease: insights for cholestatic and fatty liver diseases","volume":"87","author":"Arrese","year":"2010","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bbadis.2021.166235_bb0165","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1146\/annurev.biochem.68.1.559","article-title":"Nuclear-receptor ligands and ligand-binding domains","volume":"68","author":"Weatherman","year":"1999","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.bbadis.2021.166235_bb0170","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1074\/jbc.M110.154732","article-title":"Proteomic analysis of native hepatocyte nuclear factor-4alpha (HNF4alpha) isoforms, phosphorylation status, and interactive cofactors","volume":"286","author":"Daigo","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbadis.2021.166235_bb0175","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0083-6729(04)68009-5","article-title":"Vitamin D receptor-DNA interactions","volume":"68","author":"Shaffer","year":"2004","journal-title":"Vitam. Horm."},{"key":"10.1016\/j.bbadis.2021.166235_bb0180","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1016\/S0006-3495(97)78849-0","article-title":"How hormone receptor-DNA binding affects nucleosomal DNA: the role of symmetry","volume":"72","author":"Bishop","year":"1997","journal-title":"Biophys. J."},{"key":"10.1016\/j.bbadis.2021.166235_bb0185","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1042\/bse0400059","article-title":"DNA recognition by nuclear receptors","volume":"40","author":"Claessens","year":"2004","journal-title":"Essays Biochem."},{"key":"10.1016\/j.bbadis.2021.166235_bb0190","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S0968-0004(01)01800-X","article-title":"Nuclear-receptor interactions on DNA-response elements","volume":"26","author":"Khorasanizadeh","year":"2001","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.bbadis.2021.166235_bb0195","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1016\/j.febslet.2008.07.003","article-title":"DNA-binding profiling of human hormone nuclear receptors via fluorescence correlation spectroscopy in a cell-free system","volume":"582","author":"Kobayashi","year":"2008","journal-title":"FEBS Lett."},{"key":"10.1016\/j.bbadis.2021.166235_bb0200","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/0092-8674(95)90199-X","article-title":"The nuclear receptor superfamily: the second decade","volume":"83","author":"Mangelsdorf","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.bbadis.2021.166235_bb0205","doi-asserted-by":"crossref","unstructured":"Sever R, Glass CK. Signaling by nuclear receptors. Cold Spring Harb Perspect Biol 2013;5:a016709.","DOI":"10.1101\/cshperspect.a016709"},{"key":"10.1016\/j.bbadis.2021.166235_bb0210","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1101\/gad.14.2.121","article-title":"The coregulator exchange in transcriptional functions of nuclear receptors","volume":"14","author":"Glass","year":"2000","journal-title":"Genes Dev."},{"key":"10.1016\/j.bbadis.2021.166235_bb0215","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1021\/bi101762x","article-title":"Nuclear receptor coactivators: structural and functional biochemistry","volume":"50","author":"Bulynko","year":"2011","journal-title":"Biochemistry"},{"key":"10.1016\/j.bbadis.2021.166235_bb0220","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1093\/cvr\/cvy044","article-title":"Non-genomic effects of nuclear receptors: insights from the anucleate platelet","volume":"114","author":"Unsworth","year":"2018","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.bbadis.2021.166235_bb0225","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/hep4.1203","article-title":"Nuclear receptors and liver disease: summary of the 2017 basic research symposium","volume":"2","author":"Tran","year":"2018","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.bbadis.2021.166235_bb0230","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1128\/MCB.23.3.864-872.2003","article-title":"Identification of farnesoid X receptor beta as a novel mammalian nuclear receptor sensing lanosterol","volume":"23","author":"Otte","year":"2003","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.bbadis.2021.166235_bb0235","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/cr.2008.289","article-title":"FXR: a metabolic regulator and cell protector","volume":"18","author":"Wang","year":"2008","journal-title":"Cell Res."},{"key":"10.1016\/j.bbadis.2021.166235_bb0240","first-page":"19","article-title":"Update on FXR biology: promising therapeutic target?","author":"Han","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbadis.2021.166235_bb0245","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.tibs.2006.08.002","article-title":"FXR, a multipurpose nuclear receptor","volume":"31","author":"Lee","year":"2006","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.bbadis.2021.166235_bb0250","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.apsb.2015.01.004","article-title":"Bile acid nuclear receptor FXR and digestive system diseases","volume":"5","author":"Ding","year":"2015","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bbadis.2021.166235_bb0255","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/nrd2619","article-title":"Targeting bile-acid signalling for metabolic diseases","volume":"7","author":"Thomas","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbadis.2021.166235_bb0260","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1161\/ATVBAHA.107.152694","article-title":"Farnesoid x receptor ligands inhibit vascular smooth muscle cell inflammation and migration","volume":"27","author":"Li","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.bbadis.2021.166235_bb0265","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1002\/hep.28836","article-title":"Liver capsule: FXR agonists against liver disease","volume":"64","author":"Fuchs","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.bbadis.2021.166235_bb0270","doi-asserted-by":"crossref","first-page":"41930","DOI":"10.1074\/jbc.M306309200","article-title":"Enterohepatic circulation of bile salts in farnesoid X receptor-deficient mice: efficient intestinal bile salt absorption in the absence of ileal bile acid-binding protein","volume":"278","author":"Kok","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbadis.2021.166235_bb0275","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1158\/0008-5472.CAN-06-1078","article-title":"Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor","volume":"67","author":"Yang","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbadis.2021.166235_bb0280","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1126\/science.1121435","article-title":"Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration","volume":"312","author":"Huang","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.bbadis.2021.166235_bb0285","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.2353\/ajpath.2009.090114","article-title":"Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts","volume":"175","author":"Fickert","year":"2009","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bbadis.2021.166235_bb0290","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1124\/jpet.108.144600","article-title":"Farnesoid X receptor deficiency induces nonalcoholic steatohepatitis in low-density lipoprotein receptor-knockout mice fed a high-fat diet","volume":"328","author":"Kong","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bbadis.2021.166235_bb0295","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.biochi.2015.05.014","article-title":"Excessive bile acid activated NF-kappa B and promoted the development of alcoholic steatohepatitis in farnesoid X receptor deficient mice","volume":"115","author":"Wu","year":"2015","journal-title":"Biochimie"},{"key":"10.1016\/j.bbadis.2021.166235_bb0300","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/hep.24537","article-title":"Dual farnesoid X receptor\/TGR5 agonist INT-767 reduces liver injury in the Mdr2\u2212\/\u2212 (Abcb4\u2212\/\u2212) mouse cholangiopathy model by promoting biliary HCO(\u2212)(3) output","volume":"54","author":"Baghdasaryan","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.bbadis.2021.166235_bb0305","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1053\/j.gastro.2004.08.001","article-title":"The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis","volume":"127","author":"Fiorucci","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbadis.2021.166235_bb0310","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1124\/jpet.105.084905","article-title":"A farnesoid x receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis","volume":"314","author":"Fiorucci","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bbadis.2021.166235_bb0315","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/hep.22196","article-title":"Loss of orphan receptor small heterodimer partner sensitizes mice to liver injury from obstructive cholestasis","volume":"47","author":"Park","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.bbadis.2021.166235_bb0320","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00011-010-0306-1","article-title":"SHP-dependent and -independent induction of peroxisome proliferator-activated receptor-gamma by the bile acid sensor farnesoid X receptor counter-regulates the pro-inflammatory phenotype of liver myofibroblasts","volume":"60","author":"Renga","year":"2011","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.bbadis.2021.166235_bb0325","doi-asserted-by":"crossref","first-page":"41055","DOI":"10.1038\/srep41055","article-title":"Decoding the role of the nuclear receptor SHP in regulating hepatic stellate cells and liver fibrogenesis","volume":"7","author":"Cipriani","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbadis.2021.166235_bb0330","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1124\/mol.110.068247","article-title":"Roles of microRNA-29a in the antifibrotic effect of farnesoid X receptor in hepatic stellate cells","volume":"80","author":"Li","year":"2011","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bbadis.2021.166235_bb0335","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0013955","article-title":"Inhibition of endothelin-1-mediated contraction of hepatic stellate cells by FXR ligand","volume":"5","author":"Li","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.bbadis.2021.166235_bb0340","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1476-5926-5-5","article-title":"Endothelin-1 enhances fibrogenic gene expression, but does not promote DNA synthesis or apoptosis in hepatic stellate cells","volume":"5","author":"Koda","year":"2006","journal-title":"Comp. Hepatol."},{"key":"10.1016\/j.bbadis.2021.166235_bb0345","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jhep.2016.12.005","article-title":"The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction","volume":"66","author":"Schwabl","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbadis.2021.166235_bb0350","first-page":"9","article-title":"The non-steroidal FXR agonist cilofexor improves portal hypertension and reduces hepatic fibrosis in a rat NASH model","author":"Schwabl","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.bbadis.2021.166235_bb0355","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.bbadis.2021.166235_bb0360","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jhep.2020.02.033","article-title":"A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis","volume":"73","author":"Kowdley","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbadis.2021.166235_bb0365","doi-asserted-by":"crossref","first-page":"105803","DOI":"10.1016\/j.cct.2019.06.017","article-title":"REGENERATE: design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis","volume":"84","author":"Ratziu","year":"2019","journal-title":"Contemp. Clin. Trials"},{"key":"10.1016\/j.bbadis.2021.166235_bb0370","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cmet.2005.09.001","article-title":"Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis","volume":"2","author":"Inagaki","year":"2005","journal-title":"Cell Metab."},{"key":"10.1016\/j.bbadis.2021.166235_bb0375","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.taap.2017.06.023","article-title":"The effect of fibroblast growth factor 15 deficiency on the development of high fat diet induced non-alcoholic steatohepatitis","volume":"330","author":"Schumacher","year":"2017","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.bbadis.2021.166235_bb0380","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1002\/hep4.1108","article-title":"Engineered FGF19 eliminates bile acid toxicity and lipotoxicity leading to resolution of steatohepatitis and fibrosis in mice","volume":"1","author":"Zhou","year":"2017","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.bbadis.2021.166235_bb0385","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1016\/S0168-8278(20)30750-9","article-title":"Positive topline results from a 24-week, randomized, doubleblind, placebo-controlled, multicenter, phase 2 study of the FGF19 analogue aldafermin (NGM282) in patients with non-alcoholic steatohepatitis","volume":"73","author":"Harrison SA","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbadis.2021.166235_bb0390","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.1016\/S0168-8278(20)30750-9","article-title":"LBO01 - positive topline results from a 24-week, randomized, double-blind, placebo-controlled, multicenter, phase 2 study of the FGF19 analogue aldafermin (NGM282) in patients with non-alcoholic steatohepatitis","volume":"73","author":"Harrison","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbadis.2021.166235_bb0395","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jhep.2018.10.035","article-title":"Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: a multicenter, randomized, double-blind, placebo-controlled phase II trial","volume":"70","author":"Hirschfield","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbadis.2021.166235_bb0400","doi-asserted-by":"crossref","first-page":"6251","DOI":"10.4049\/jimmunol.0803978","article-title":"The bile acid receptor FXR is a modulator of intestinal innate immunity","volume":"183","author":"Vavassori","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.bbadis.2021.166235_bb0405","doi-asserted-by":"crossref","first-page":"3920","DOI":"10.1073\/pnas.0509592103","article-title":"Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor","volume":"103","author":"Inagaki","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbadis.2021.166235_bb0410","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.jhep.2015.12.010","article-title":"Obeticholic acid reduces bacterial translocation and inhibits intestinal inflammation in cirrhotic rats","volume":"64","author":"Ubeda","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbadis.2021.166235_bb0415","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1124\/mol.117.111047","article-title":"Effects of farnesoid X receptor activation on arachidonic acid metabolism, NF-kB signaling, and hepatic inflammation","volume":"94","author":"Gai","year":"2018","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bbadis.2021.166235_bb0420","first-page":"1455","article-title":"GW4064 attenuates lipopolysaccharideinduced hepatic inflammation and apoptosis through inhibition of the Tolllike receptor 4mediated p38 mitogenactivated protein kinase signaling pathway in mice","volume":"41","author":"Liu","year":"2018","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.bbadis.2021.166235_bb0425","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/j.cellsig.2012.04.015","article-title":"FXR ligands protect against hepatocellular inflammation via SOCS3 induction","volume":"24","author":"Xu","year":"2012","journal-title":"Cell. Signal."},{"key":"10.1016\/j.bbadis.2021.166235_bb0430","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1038\/s41598-020-58562-x","article-title":"Obeticholic acid and INT-767 modulate collagen deposition in a NASH in vitro model","volume":"10","author":"Anfuso","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbadis.2021.166235_bb0435","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jhep.2009.03.025","article-title":"Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis","volume":"51","author":"Zhang","year":"2009","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbadis.2021.166235_bb0440","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1016\/j.bmcl.2016.05.070","article-title":"Novel substituted isoxazole FXR agonists with cyclopropyl, hydroxycyclobutyl and hydroxyazetidinyl linkers: understanding and improving key determinants of pharmacological properties","volume":"26","author":"Kinzel","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bbadis.2021.166235_bb0445","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.2174\/1568026614666141112094430","article-title":"Knocking on FXR\u2019s door: the \u201chammerhead\u201d-structure series of FXR agonists - amphiphilic isoxazoles with potent in vitro and in vivo activities","volume":"14","author":"Gege","year":"2014","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.bbadis.2021.166235_bb0450","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1055\/s-0039-1693115","article-title":"Vascular targets for the treatment of portal hypertension","volume":"39","author":"Brusilovskaya","year":"2019","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.bbadis.2021.166235_bb0455","doi-asserted-by":"crossref","unstructured":"Patel K, Harrison SA, Elkhashab M, et al. Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH: A phase 2 randomized controlled trial. Hepatology 2020;72:58\u201371.","DOI":"10.1002\/hep.31205"},{"key":"10.1016\/j.bbadis.2021.166235_bb0460","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/hep.31622","article-title":"Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis attributable to NASH","volume":"73","author":"Loomba","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.bbadis.2021.166235_bb0465","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.cell.2006.06.049","article-title":"Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network","volume":"126","author":"Bookout","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.bbadis.2021.166235_bb0470","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1053\/jhep.2003.50176","article-title":"The normal liver harbors the vitamin D nuclear receptor in nonparenchymal and biliary epithelial cells","volume":"37","author":"Gascon-Barr\u00e9","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.bbadis.2021.166235_bb0475","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.cell.2013.03.028","article-title":"A vitamin D receptor\/SMAD genomic circuit gates hepatic fibrotic response","volume":"153","author":"Ding","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.bbadis.2021.166235_bb0480","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1136\/gut.2010.234666","article-title":"Vitamin D inhibits proliferation and profibrotic marker expression in hepatic stellate cells and decreases thioacetamide-induced liver fibrosis in rats","volume":"60","author":"Abramovitch","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.bbadis.2021.166235_bb0485","doi-asserted-by":"crossref","first-page":"G112","DOI":"10.1152\/ajpgi.00132.2013","article-title":"Vitamin D inhibits development of liver fibrosis in an animal model but cannot ameliorate established cirrhosis","volume":"308","author":"Abramovitch","year":"2015","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.bbadis.2021.166235_bb0490","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s12072-014-9548-2","article-title":"Vitamin D modulates biliary fibrosis in ABCB4-deficient mice","volume":"8","author":"Hochrath","year":"2014","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.bbadis.2021.166235_bb0495","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.biopha.2018.10.140","article-title":"Vitamin D and liver fibrosis: molecular mechanisms and clinical studies","volume":"109","author":"Udomsinprasert","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bbadis.2021.166235_bb0500","doi-asserted-by":"crossref","first-page":"340","DOI":"10.11138\/ccmbm\/2017.14.3.340","article-title":"Calcitriol-mediated hypercalcemia secondary to granulomatous disease caused by soft-tissue filler injection: a case report","volume":"14","author":"Norena","year":"2017","journal-title":"Clin. Cases Miner. Bone Metab."},{"key":"10.1016\/j.bbadis.2021.166235_bb0505","doi-asserted-by":"crossref","first-page":"742","DOI":"10.5604\/01.3001.0010.2748","article-title":"Effect of vitamin D serum levels and GC gene polymorphisms in liver fibrosis due to chronic hepatitis C","volume":"16","author":"Azevedo","year":"2017","journal-title":"Ann. Hepatol."},{"key":"10.1016\/j.bbadis.2021.166235_bb0510","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/j.1478-3231.2011.02674.x","article-title":"Combined effect of 25-OH vitamin D plasma levels and genetic vitamin D receptor (NR 1I1) variants on fibrosis progression rate in HCV patients","volume":"32","author":"Baur","year":"2012","journal-title":"Liver Int."},{"key":"10.1016\/j.bbadis.2021.166235_bb0515","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/jvh.12072","article-title":"Association of vitamin D serum levels and its common genetic determinants, with severity of liver fibrosis in genotype 1 chronic hepatitis C patients","volume":"20","author":"Petta","year":"2013","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.bbadis.2021.166235_bb0520","doi-asserted-by":"crossref","unstructured":"Hazra S, Miyahara T, Rippe RA, et al. PPAR gamma and hepatic stellate cells. Comp. Hepatol. 2004;3 Suppl 1:S7.","DOI":"10.1186\/1476-5926-2-S1-S7"},{"key":"10.1016\/j.bbadis.2021.166235_bb0525","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1210\/endo.137.1.8536636","article-title":"Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat","volume":"137","author":"Braissant","year":"1996","journal-title":"Endocrinology"},{"key":"10.1016\/j.bbadis.2021.166235_bb0530","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.plipres.2005.12.002","article-title":"From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions","volume":"45","author":"Feige","year":"2006","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.bbadis.2021.166235_bb0535","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1146\/annurev.med.53.082901.104018","article-title":"The mechanisms of action of PPARs","volume":"53","author":"Berger","year":"2002","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.bbadis.2021.166235_bb0540","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.jhep.2020.11.045","article-title":"Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease","volume":"74","author":"Boyer-Diaz","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbadis.2021.166235_bb0545","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/384039a0","article-title":"The PPARalpha-leukotriene B4 pathway to inflammation control","volume":"384","author":"Devchand","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.bbadis.2021.166235_bb0550","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00011-019-01231-1","article-title":"Self-regulation of the inflammatory response by peroxisome proliferator-activated receptors","volume":"68","author":"Korbecki","year":"2019","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.bbadis.2021.166235_bb0555","doi-asserted-by":"crossref","first-page":"G283","DOI":"10.1152\/ajpgi.00205.2016","article-title":"Hepatocyte-specific PPARA expression exclusively promotes agonist-induced cell proliferation without influence from nonparenchymal cells","volume":"312","author":"Brocker","year":"2017","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.bbadis.2021.166235_bb0560","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/hep.20170","article-title":"Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice","volume":"39","author":"Ip","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.bbadis.2021.166235_bb0565","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1002\/hep.27297","article-title":"The transrepressive activity of peroxisome proliferator-activated receptor alpha is necessary and sufficient to prevent liver fibrosis in mice","volume":"60","author":"Pawlak","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.bbadis.2021.166235_bb0570","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.jhep.2011.12.008","article-title":"PPARalpha activation improves endothelial dysfunction and reduces fibrosis and portal pressure in cirrhotic rats","volume":"56","author":"Rodriguez-Vilarrupla","year":"2012","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbadis.2021.166235_bb0575","doi-asserted-by":"crossref","first-page":"42530","DOI":"10.18632\/oncotarget.6466","article-title":"Oleoylethanolamide, an endogenous PPAR-alpha ligand, attenuates liver fibrosis targeting hepatic stellate cells","volume":"6","author":"Chen","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbadis.2021.166235_bb0580","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/nrendo.2010.89","article-title":"PPARalpha: an emerging therapeutic target in diabetic microvascular damage","volume":"6","author":"Hiukka","year":"2010","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.bbadis.2021.166235_bb0585","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1172\/JCI27989","article-title":"Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis","volume":"116","author":"Lefebvre","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbadis.2021.166235_bb0590","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1161\/01.HYP.0000187900.36455.4c","article-title":"Beneficial vascular and metabolic effects of peroxisome proliferator-activated receptor-alpha activators","volume":"46","author":"Han","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.bbadis.2021.166235_bb0595","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0378-4274(99)00243-X","article-title":"Apoptosis and proliferation in nongenotoxic carcinogenesis: species differences and role of PPARalpha","volume":"112-113","author":"Roberts","year":"2000","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.bbadis.2021.166235_bb0600","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1186\/s12864-018-4834-3","article-title":"The whole transcriptome effects of the PPARalpha agonist fenofibrate on livers of hepatocyte humanized mice","volume":"19","author":"de la Rosa Rodriguez","year":"2018","journal-title":"BMC Genomics"},{"key":"10.1016\/j.bbadis.2021.166235_bb0605","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0006796","article-title":"Comparative analysis of gene regulation by the transcription factor PPARalpha between mouse and human","volume":"4","author":"Rakhshandehroo","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.bbadis.2021.166235_bb0610","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1146\/annurev.biochem.74.082803.133329","article-title":"Biochemistry of mammalian peroxisomes revisited","volume":"75","author":"Wanders","year":"2006","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.bbadis.2021.166235_bb0615","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41575-020-00366-5","article-title":"Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors","volume":"18","author":"Francque","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbadis.2021.166235_bb0620","doi-asserted-by":"crossref","first-page":"G722","DOI":"10.1152\/ajpgi.00411.2003","article-title":"Tumor necrosis factor-alpha inhibits peroxisome proliferator-activated receptor gamma activity at a posttranslational level in hepatic stellate cells","volume":"286","author":"Sung","year":"2004","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.bbadis.2021.166235_bb0625","doi-asserted-by":"crossref","first-page":"G7","DOI":"10.1152\/ajpgi.2000.279.1.G7","article-title":"New insights into hepatic stellate cell activation: the simple becomes complex","volume":"279","author":"Eng","year":"2000","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.bbadis.2021.166235_bb0630","doi-asserted-by":"crossref","first-page":"35715","DOI":"10.1074\/jbc.M006577200","article-title":"Peroxisome proliferator-activated receptors and hepatic stellate cell activation","volume":"275","author":"Miyahara","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbadis.2021.166235_bb0635","doi-asserted-by":"crossref","first-page":"11392","DOI":"10.1074\/jbc.M310284200","article-title":"Peroxisome proliferator-activated receptor gamma induces a phenotypic switch from activated to quiescent hepatic stellate cells","volume":"279","author":"Hazra","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbadis.2021.166235_bb0640","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1002\/art.20104","article-title":"Disruption of transforming growth factor beta signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor gamma","volume":"50","author":"Ghosh","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bbadis.2021.166235_bb0645","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1053\/gast.2000.9365","article-title":"Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells","volume":"119","author":"Marra","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbadis.2021.166235_bb0650","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1053\/gast.2002.33666","article-title":"Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro","volume":"122","author":"Galli","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbadis.2021.166235_bb0655","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.bbrc.2006.09.069","article-title":"PPARgamma agonists prevent TGFbeta1\/Smad3-signaling in human hepatic stellate cells","volume":"350","author":"Zhao","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbadis.2021.166235_bb0660","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.bbrc.2004.01.038","article-title":"Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet","volume":"315","author":"Kawaguchi","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbadis.2021.166235_bb0665","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1053\/j.gastro.2003.12.008","article-title":"Pioglitazone prevents alcohol-induced fatty liver in rats through up-regulation of c-Met","volume":"126","author":"Tomita","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbadis.2021.166235_bb0670","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/hep.510310117","article-title":"Peroxisome proliferator-activated receptor gamma transcriptional regulation is involved in platelet-derived growth factor-induced proliferation of human hepatic stellate cells","volume":"31","author":"Galli","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.bbadis.2021.166235_bb0675","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1046\/j.1523-1755.2003.00054.x","article-title":"PPARgamma ligand attenuates PDGF-induced mesangial cell proliferation: role of MAP kinase","volume":"64","author":"Ghosh","year":"2003","journal-title":"Kidney Int."},{"key":"10.1016\/j.bbadis.2021.166235_bb0680","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/34178","article-title":"The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation","volume":"391","author":"Ricote","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.bbadis.2021.166235_bb0685","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jhep.2013.06.023","article-title":"Cell-specific PPARgamma deficiency establishes anti-inflammatory and anti-fibrogenic properties for this nuclear receptor in non-parenchymal liver cells","volume":"59","author":"Moran-Salvador","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbadis.2021.166235_bb0690","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/gut.2005.079194","article-title":"Limited therapeutic efficacy of pioglitazone on progression of hepatic fibrosis in rats","volume":"55","author":"Leclercq","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.bbadis.2021.166235_bb0695","unstructured":"Jain MR GS, Bhoi B, Rathod R, Trivedi C, Rath AC, Sharma A, Patel U, Patel H, Ranvir R, Saroglitazar attenuates primary sclerosing cholangitis in MDR\u2212\/\u2212 mice model: a comparison with obeticholic acid. Hepatology 2020;72m Number 1 (Suppl) - 1270."},{"key":"10.1016\/j.bbadis.2021.166235_bb0700","unstructured":"Siddiqui M IM, Parmar DV, Borg B, Douglas D, Loo NM, Lazas D, Younes ZH, Vellanki R, Bainbridge JD, Sanyal AJ. Saroglitazar, adual PPAR\u03b1\/\u03b3 agonist, resolved steatohepatitis in a randomized double blind placebo controlled phase 2 proof of concept pilot trial. HEPATOLOGY 2020;72, Number 1 (Suppl) - 1695."},{"key":"10.1016\/j.bbadis.2021.166235_bb0705","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1194\/jlr.M200376-JLR200","article-title":"PPARbeta regulates vitamin A metabolism-related gene expression in hepatic stellate cells undergoing activation","volume":"44","author":"Hellemans","year":"2003","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.bbadis.2021.166235_bb0710","first-page":"19","article-title":"Insights into the role of PPARbeta\/delta in NAFLD","author":"Chen","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbadis.2021.166235_bb0715","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1073\/pnas.012610299","article-title":"Effects of peroxisome proliferator-activated receptor delta on placentation, adiposity, and colorectal cancer","volume":"99","author":"Barak","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbadis.2021.166235_bb0720","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1146\/annurev-pathol-011110-130138","article-title":"Alternative macrophage activation and metabolism","volume":"6","author":"Odegaard","year":"2011","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.bbadis.2021.166235_bb0725","doi-asserted-by":"crossref","first-page":"20874","DOI":"10.1074\/jbc.M312802200","article-title":"Peroxisome proliferator-activated receptor beta\/delta regulates very low density lipoprotein production and catabolism in mice on a Western diet","volume":"279","author":"Akiyama","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbadis.2021.166235_bb0730","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1093\/toxsci\/kfn142","article-title":"Ligand activation of peroxisome proliferator-activated receptor beta\/delta (PPARbeta\/delta) attenuates carbon tetrachloride hepatotoxicity by downregulating proinflammatory gene expression","volume":"105","author":"Shan","year":"2008","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.bbadis.2021.166235_bb0735","doi-asserted-by":"crossref","first-page":"E1369","DOI":"10.1073\/pnas.1202464109","article-title":"Protection from liver fibrosis by a peroxisome proliferator-activated receptor delta agonist","volume":"109","author":"Iwaisako","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbadis.2021.166235_bb0740","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1053\/gast.2003.50015","article-title":"Peroxisome proliferator-activated receptor-beta signaling contributes to enhanced proliferation of hepatic stellate cells","volume":"124","author":"Hellemans","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbadis.2021.166235_bb0745","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/2045-3701-2-34","article-title":"GW501516-activated PPARbeta\/delta promotes liver fibrosis via p38-JNK MAPK-induced hepatic stellate cell proliferation","volume":"2","author":"Kostadinova","year":"2012","journal-title":"Cell Biosci."},{"key":"10.1016\/j.bbadis.2021.166235_bb0750","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/hep.26461","article-title":"Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha\/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"58","author":"Staels","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.bbadis.2021.166235_bb0755","first-page":"9","article-title":"Peroxisome proliferator-activated receptors and their novel ligands as candidates for the treatment of non-alcoholic fatty liver disease","author":"Fougerat","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.bbadis.2021.166235_bb0760","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.4254\/wjh.v7.i8.1012","article-title":"Peroxisome proliferator-activated receptors as targets to treat non-alcoholic fatty liver disease","volume":"7","author":"Souza-Mello","year":"2015","journal-title":"World J. Hepatol."},{"issue":"6","key":"10.1016\/j.bbadis.2021.166235_bb0765","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jhep.2021.01.013","article-title":"A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA","volume":"74","author":"Schattenberg","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbadis.2021.166235_bb0770","unstructured":"Francque SM BP, Ratziu V, Anstee QM, Bugianesi E, Sanyal AJ, Loomba R, Harrison SA, Balabanska IR, Mateva L, Lanthier N, Alkhouri N, Moreno C, Schattenberg JM, Stefanova-Petrova D, Vonghia L, Rouzier R, Guillaume M, Leroy V, Romero-Gomez M, Hodge AD, Huot-Marchand P, Sabin N, Baudin M, Abitbol J, Broqua P, Junien J, Abdelmalek MF. The panPPAR agonist Lanifibranor induces both resolution of NASH and regression of fibrosis after 24 weeks of treatment in non-cirrhotic NASH: results of the native phase 2b trial. HEPATOLOGY 2020;72, Number 1 (Suppl) - Abstract 12."},{"key":"10.1016\/j.bbadis.2021.166235_bb0775","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","article-title":"A placebo-controlled trial of bezafibrate in primary biliary cholangitis","volume":"378","author":"Corpechot","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbadis.2021.166235_bb0780","doi-asserted-by":"crossref","first-page":"37973","DOI":"10.1074\/jbc.M112.403139","article-title":"A role for protein inhibitor of activated STAT1 (PIAS1) in lipogenic regulation through SUMOylation-independent suppression of liver X receptors","volume":"287","author":"Zhang","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbadis.2021.166235_bb0785","doi-asserted-by":"crossref","unstructured":"Lopez-Velazquez JA, Carrillo-Cordova LD, Chavez-Tapia NC, et al. Nuclear receptors in nonalcoholic fatty liver disease. J. Lipids 2012;2012:139875.","DOI":"10.1155\/2012\/139875"},{"key":"10.1016\/j.bbadis.2021.166235_bb0790","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1053\/j.gastro.2010.11.053","article-title":"Liver X receptor signaling is a determinant of stellate cell activation and susceptibility to fibrotic liver disease","volume":"140","author":"Beaven","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbadis.2021.166235_bb0795","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.jhep.2011.05.018","article-title":"The liver X receptor in hepatic stellate cells: a novel antifibrogenic target?","volume":"55","author":"Mallat","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbadis.2021.166235_bb0800","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/01.shk.0000191377.78144.d9","article-title":"Activation of the liver X receptor protects against hepatic injury in endotoxemia by suppressing Kupffer cell activation","volume":"25","author":"Wang","year":"2006","journal-title":"Shock"},{"key":"10.1016\/j.bbadis.2021.166235_bb0805","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1194\/jlr.M006486","article-title":"Macrophage ABCA1 reduces MyD88-dependent Toll-like receptor trafficking to lipid rafts by reduction of lipid raft cholesterol","volume":"51","author":"Zhu","year":"2010","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.bbadis.2021.166235_bb0810","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.08009","article-title":"LXRs link metabolism to inflammation through Abca1-dependent regulation of membrane composition and TLR signaling","volume":"4","author":"Ito","year":"2015","journal-title":"Elife"},{"key":"10.1016\/j.bbadis.2021.166235_bb0815","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1172\/JCI27883","article-title":"Liver X receptors as integrators of metabolic and inflammatory signaling","volume":"116","author":"Zelcer","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbadis.2021.166235_bb0820","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1755-5922.2008.00062.x","article-title":"Liver X receptors (LXR) as therapeutic targets in dyslipidemia","volume":"26","author":"Beltowski","year":"2008","journal-title":"Cardiovasc. Ther."},{"key":"10.1016\/j.bbadis.2021.166235_bb0825","doi-asserted-by":"crossref","first-page":"21309","DOI":"10.1038\/srep21309","article-title":"Liver X receptor alpha is essential for the capillarization of liver sinusoidal endothelial cells in liver injury","volume":"6","author":"Xing","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbadis.2021.166235_bb0830","first-page":"9","article-title":"The endothelium as a driver of liver fibrosis and regeneration","author":"Lafoz","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.bbadis.2021.166235_bb0835","doi-asserted-by":"crossref","unstructured":"Huang P, Kaluba B, Jiang XL, et al. Liver X receptor inverse agonist SR9243 suppresses nonalcoholic Steatohepatitis intrahepatic inflammation and fibrosis. Biomed. Res. Int. 2018;2018:8071093.","DOI":"10.1155\/2018\/8071093"},{"key":"10.1016\/j.bbadis.2021.166235_bb0840","doi-asserted-by":"crossref","unstructured":"Griffett K, Welch RD, Flaveny CA, et al. The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis. Mol Metab 2015;4:353\u20137.","DOI":"10.1016\/j.molmet.2015.01.009"},{"key":"10.1016\/j.bbadis.2021.166235_bb0845","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/hep.24148","article-title":"Nuclear receptors in liver disease","volume":"53","author":"Wagner","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.bbadis.2021.166235_bb0850","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S0022-2275(20)32030-7","article-title":"An immortalized rat liver stellate cell line (HSC-T6): a new cell model for the study of retinoid metabolism in vitro","volume":"41","author":"Vogel","year":"2000","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.bbadis.2021.166235_bb0855","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0171-9335(98)80078-2","article-title":"Expression of retinoic acid receptor and retinoid X receptor subtypes in rat liver cells: implications for retinoid signalling in parenchymal, endothelial, Kupffer and stellate cells","volume":"77","author":"Ulven","year":"1998","journal-title":"Eur. J. Cell Biol."},{"key":"10.1016\/j.bbadis.2021.166235_bb0860","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s10822-015-9869-9","article-title":"Docking simulations suggest that all-trans retinoic acid could bind to retinoid X receptors","volume":"29","author":"Tsuji","year":"2015","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.bbadis.2021.166235_bb0865","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3390\/ijms14010226","article-title":"The controversial role of retinoic acid in fibrotic diseases: analysis of involved signaling pathways","volume":"14","author":"Zhou","year":"2012","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbadis.2021.166235_bb0870","first-page":"913","article-title":"Retinoids exacerbate rat liver fibrosis by inducing the activation of latent TGF-beta in liver stellate cells","volume":"26","author":"Okuno","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/j.bbadis.2021.166235_bb0875","doi-asserted-by":"crossref","first-page":"d204","DOI":"10.2741\/okuno","article-title":"Retinoids in liver fibrosis and cancer","volume":"7","author":"Okuno","year":"2002","journal-title":"Front. Biosci."},{"key":"10.1016\/j.bbadis.2021.166235_bb0880","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1007\/s11596-010-0648-5","article-title":"All-trans retinoic acid diminishes collagen production in a hepatic stellate cell line via suppression of active protein-1 and c-Jun N-terminal kinase signal","volume":"30","author":"Ye","year":"2010","journal-title":"J. Huazhong Univ. Sci. Technolog. Med. Sci."},{"key":"10.1016\/j.bbadis.2021.166235_bb0885","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/hep.20015","article-title":"Differential modulation of rat hepatic stellate phenotype by natural and synthetic retinoids","volume":"39","author":"Hellemans","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.bbadis.2021.166235_bb0890","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/hep.30193","article-title":"Retinoic acid receptor-beta is downregulated in hepatocellular carcinoma and cirrhosis and its expression inhibits myosin-driven activation and durotaxis in hepatic stellate cells","volume":"69","author":"Cortes","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.bbadis.2021.166235_bb0895","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s11596-008-0514-x","article-title":"Effect of all-trans retinoic acid on liver fibrosis induced by common bile duct ligation in rats","volume":"28","author":"Wang","year":"2008","journal-title":"J. Huazhong Univ. Sci. Technolog. Med. Sci."},{"key":"10.1016\/j.bbadis.2021.166235_bb0900","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/hep.24047","article-title":"Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct-ligated rats and human hepatic cells","volume":"53","author":"He","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.bbadis.2021.166235_bb0905","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1124\/jpet.113.209353","article-title":"All-trans-retinoic acid improves cholestasis in alpha-naphthylisothiocyanate-treated rats and Mdr2\u2212\/\u2212 mice","volume":"349","author":"Cai","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bbadis.2021.166235_bb0910","doi-asserted-by":"crossref","first-page":"19002","DOI":"10.1074\/jbc.M109.068460","article-title":"Transcriptional regulation of cannabinoid receptor-1 expression in the liver by retinoic acid acting via retinoic acid receptor-gamma","volume":"285","author":"Mukhopadhyay","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbadis.2021.166235_bb0915","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.bbadis.2006.08.009","article-title":"Effects of retinoic acid on the development of liver fibrosis produced by carbon tetrachloride in mice","volume":"1772","author":"Wang","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbadis.2021.166235_bb0920","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1111\/j.1478-3231.2008.01745.x","article-title":"All-trans-retinoic acid ameliorates carbon tetrachloride-induced liver fibrosis in mice through modulating cytokine production","volume":"28","author":"Hisamori","year":"2008","journal-title":"Liver Int."},{"key":"10.1016\/j.bbadis.2021.166235_bb0925","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.bbrc.2007.10.203","article-title":"Antagonizing TGF-beta induced liver fibrosis by a retinoic acid derivative through regulation of ROS and calcium influx","volume":"365","author":"Yang","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbadis.2021.166235_bb0930","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/S0168-8278(99)80262-1","article-title":"Increased 9,13-di-cis-retinoic acid in rat hepatic fibrosis: implication for a potential link between retinoid loss and TGF-beta mediated fibrogenesis in vivo","volume":"30","author":"Okuno","year":"1999","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbadis.2021.166235_bb0935","doi-asserted-by":"crossref","unstructured":"le Maire A, Teyssier C, Balaguer P, et al. Regulation of RXR-RAR heterodimers by RXR- and RAR-specific ligands and their combinations. Cells 2019;8.","DOI":"10.3390\/cells8111392"},{"key":"10.1016\/j.bbadis.2021.166235_bb0940","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3389\/fmed.2020.00331","article-title":"Selective thyroid hormone receptor-beta (TRbeta) agonists: new perspectives for the treatment of metabolic and neurodegenerative disorders","volume":"7","author":"Saponaro","year":"2020","journal-title":"Front. Med. (Lausanne)"},{"key":"10.1016\/j.bbadis.2021.166235_bb0945","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s42000-020-00208-8","article-title":"Relationship of thyroid dysfunction with cardiovascular diseases: updated review on heart failure progression","volume":"19","author":"Abdel-Moneim","year":"2020","journal-title":"Hormones (Athens)"},{"key":"10.1016\/j.bbadis.2021.166235_bb0950","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/s10620-011-2006-2","article-title":"Prevalence of hypothyroidism in nonalcoholic fatty liver disease","volume":"57","author":"Pagadala","year":"2012","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.bbadis.2021.166235_bb0955","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1210\/jc.2016-1300","article-title":"Thyroid function and the risk of nonalcoholic fatty liver disease: the Rotterdam study","volume":"101","author":"Bano","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bbadis.2021.166235_bb0960","doi-asserted-by":"crossref","first-page":"S582","DOI":"10.1016\/S0168-8278(17)31587-8","article-title":"Thyroid hormone receptor regulates hepatic stellate cell activation","volume":"66","author":"Manka","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbadis.2021.166235_bb0965","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1042\/BJ20041598","article-title":"Pregnenolone-16alpha-carbonitrile inhibits rodent liver fibrogenesis via PXR (pregnane X receptor)-dependent and PXR-independent mechanisms","volume":"387","author":"Marek","year":"2005","journal-title":"Biochem. J."},{"key":"10.1016\/j.bbadis.2021.166235_bb0970","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-5926-8-1","article-title":"Low affinity glucocorticoid binding site ligands as potential anti-fibrogenics","volume":"8","author":"Marek","year":"2009","journal-title":"Comp. Hepatol."},{"key":"10.1016\/j.bbadis.2021.166235_bb0975","doi-asserted-by":"crossref","first-page":"6955","DOI":"10.1016\/S0021-9258(18)48184-7","article-title":"The effects of dexamethasone on in vitro collagen gene expression","volume":"262","author":"Weiner","year":"1987","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbadis.2021.166235_bb0980","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/j.bbrc.2004.10.164","article-title":"Glucocorticoids decrease the bioavailability of TGF-beta which leads to a reduced TGF-beta signaling in hepatic stellate cells","volume":"325","author":"Bolkenius","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbadis.2021.166235_bb0985","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1210\/me.2016-1029","article-title":"Glucocorticoids have opposing effects on liver fibrosis in hepatic stellate and immune cells","volume":"30","author":"Kim","year":"2016","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.bbadis.2021.166235_bb0990","first-page":"3925","article-title":"Selective glucocorticoid receptor modulation prevents and reverses nonalcoholic fatty liver disease in male mice","volume":"159","author":"Koorneef","year":"2018","journal-title":"Endocrinology"},{"key":"10.1016\/j.bbadis.2021.166235_bb0995","doi-asserted-by":"crossref","DOI":"10.1007\/s40618-021-01522-7","article-title":"Treatment potential of LPCN 1144 on liver health and metabolic regulation in a non-genomic, high fat diet induced NASH rabbit model","author":"Comeglio","year":"2021","journal-title":"J. Endocrinol. Invest."},{"key":"10.1016\/j.bbadis.2021.166235_bb1000","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1034\/j.1600-0676.2003.00811.x","article-title":"Impact of oestrogens on the progression of liver disease","volume":"23","author":"Shimizu","year":"2003","journal-title":"Liver Int."},{"key":"10.1016\/j.bbadis.2021.166235_bb1005","doi-asserted-by":"crossref","first-page":"883","DOI":"10.3748\/wjg.v8.i5.883","article-title":"Estrogen reduces CCL4- induced liver fibrosis in rats","volume":"8","author":"Xu","year":"2002","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.bbadis.2021.166235_bb1010","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/hep.510290307","article-title":"Suppressive effects of estradiol on dimethylnitrosamine-induced fibrosis of the liver in rats","volume":"29","author":"Yasuda","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.bbadis.2021.166235_bb1015","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/S0168-8278(00)00097-0","article-title":"Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c","volume":"34","author":"Poynard","year":"2001","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbadis.2021.166235_bb1020","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1136\/gut.2006.101931","article-title":"Liver fibrosis in women with chronic hepatitis C: evidence for the negative role of the menopause and steatosis and the potential benefit of hormone replacement therapy","volume":"56","author":"Codes","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.bbadis.2021.166235_bb1025","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1590\/S1413-86702007000300014","article-title":"Chronic hepatitis C and fibrosis: evidences for possible estrogen benefits","volume":"11","author":"Codes","year":"2007","journal-title":"Braz. J. Infect. Dis."},{"key":"10.1016\/j.bbadis.2021.166235_bb1030","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.jhep.2005.11.009","article-title":"Natural history and predictors of disease severity in chronic hepatitis C","volume":"44","author":"Massard","year":"2006","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbadis.2021.166235_bb1035","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1210\/me.2009-0482","article-title":"A novel bile acid-activated vitamin D receptor signaling in human hepatocytes","volume":"24","author":"Han","year":"2010","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.bbadis.2021.166235_bb1040","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1053\/jhep.2003.50176","article-title":"The normal liver harbors the vitamin D nuclear receptor in nonparenchymal and biliary epithelial cells","volume":"37","author":"Gascon-Barre","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.bbadis.2021.166235_bb1045","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jhep.2014.10.039","article-title":"Molecular mechanism of PPARalpha action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease","volume":"62","author":"Pawlak","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbadis.2021.166235_bb1050","doi-asserted-by":"crossref","unstructured":"Burri L, Thoresen GH, Berge RK. The role of PPARalpha activation in liver and muscle. PPAR Res. 2010;2010.","DOI":"10.1155\/2010\/542359"},{"key":"10.1016\/j.bbadis.2021.166235_bb1055","first-page":"21","article-title":"PPARs as metabolic regulators in the liver: lessons from liver-specific PPAR-null mice","author":"Wang","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbadis.2021.166235_bb1060","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00018-012-1046-x","article-title":"Peroxisome proliferator-activated receptor-gamma as a therapeutic target for hepatic fibrosis: from bench to bedside","volume":"70","author":"Zhang","year":"2013","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.bbadis.2021.166235_bb1065","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1111\/acer.13049","article-title":"Hepatic peroxisome proliferator-activated receptor gamma signaling contributes to alcohol-induced hepatic Steatosis and inflammation in mice","volume":"40","author":"Zhang","year":"2016","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.bbadis.2021.166235_bb1070","first-page":"19","article-title":"The role of PPAR-delta in metabolism, inflammation, and cancer: many characters of a critical transcription factor","author":"Liu","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbadis.2021.166235_bb1075","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.2353\/ajpath.2010.091010","article-title":"Peroxisome proliferator-activated receptor {delta} regulates inflammation via NF-{kappa}B signaling in polymicrobial sepsis","volume":"177","author":"Zingarelli","year":"2010","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bbadis.2021.166235_bb1080","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41419-019-1458-8","article-title":"PPARdelta attenuates hepatic steatosis through autophagy-mediated fatty acid oxidation","volume":"10","author":"Tong","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbadis.2021.166235_bb1085","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1007\/s10620-014-3289-x","article-title":"Expression of liver X receptor correlates with intrahepatic inflammation and fibrosis in patients with nonalcoholic fatty liver disease","volume":"59","author":"Ahn","year":"2014","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.bbadis.2021.166235_bb1090","doi-asserted-by":"crossref","unstructured":"Thomas DG, Doran AC, Fotakis P, et al. LXR suppresses inflammatory gene expression and neutrophil migration through cis-repression and cholesterol efflux. Cell Rep. 2018;25:3774\u20133785 e4.","DOI":"10.1016\/j.celrep.2018.11.100"},{"key":"10.1016\/j.bbadis.2021.166235_bb1095","series-title":"Stimulation of cholesterol efflux by LXR agonists in cholesterol-loaded human macrophages is ABCA1-dependent but ABCG1-independent","first-page":"1930","volume":"29","author":"Larrede","year":"2009"},{"key":"10.1016\/j.bbadis.2021.166235_bb1100","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.3168\/jds.2010-3202","article-title":"Activation of liver X receptor (LXR) enhances de novo fatty acid synthesis in bovine mammary epithelial cells","volume":"93","author":"McFadden","year":"2010","journal-title":"J. Dairy Sci."},{"key":"10.1016\/j.bbadis.2021.166235_bb1105","article-title":"Activation of the liver X receptor by agonist TO901317 improves hepatic insulin resistance via suppressing reactive oxygen species and JNK pathway","volume":"10","author":"Dong","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.bbadis.2021.166235_bb1110","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/hep4.1657","article-title":"Effects of resmetirom on noninvasive endpoints in a 36-week phase 2 active treatment extension study in patients with NASH","volume":"5","author":"Harrison","year":"2021","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.bbadis.2021.166235_bb1115","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.bbadis.2021.166235_bb1120","first-page":"S19","article-title":"VK2809, a novel liver-directed thyroid receptor agonist, produces durable reductions in liver fat in patients with non-alcoholic fatty liver disease: results of 4-week follow-up assessment from a 12-week phase 2 randomized, placebo-controlled trial","volume":"73","author":"Loomba R","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbadis.2021.166235_bb1125","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1210\/endo-125-1-459","volume":"125","author":"Day","year":"1989","journal-title":"Endocrinology"},{"key":"10.1016\/j.bbadis.2021.166235_bb1130","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1073\/pnas.0705286104","article-title":"The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans","volume":"105","author":"Berkenstam","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbadis.2021.166235_bb1135","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1210\/me.2002-0009","article-title":"Requirement for thyroid hormone receptor beta in T3 regulation of cholesterol metabolism in mice","volume":"16","author":"Gullberg","year":"2002","journal-title":"Mol. Endocrinol."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092544392100168X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092544392100168X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T05:10:29Z","timestamp":1760418629000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092544392100168X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":227,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S092544392100168X"],"URL":"https:\/\/doi.org\/10.1016\/j.bbadis.2021.166235","relation":{},"ISSN":["0925-4439"],"issn-type":[{"value":"0925-4439","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nuclear receptors in liver fibrosis","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbadis.2021.166235","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"166235"}}